Crowdonomics
All companies

HealthLynked Corp

Public

Healthcare · Naples, FL

Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$6,020,000
Crowd $0 · Private $6.0M · 4 rounds since 2014
Latest share price
$3.25
Reg A Offering (2025) offering price

Financials

FY2016–FY2025 · from SEC filings · hover any figure for its source
$2.3M
−$5.8M
2018
$4.0M
−$5.5M
2019
$6.1M
−$5.8M
2020
$9.2M
−$10.4M
2021
$5.9M
−$8.8M
2022
$5.7M
−$1.0M
2023
$3.0M
−$6.1M
2024
$2.1M
−$3.3M
2025
RevenueNet income — beside revenue when positive, below the line when a loss

Chart shows the most recent 8 fiscal years; 2 earlier years are in the table below.

Metric
FY2016 audited
FY2017 audited
FY2018 audited
FY2019 audited
FY2020 audited
FY2021 audited
FY2022 audited
FY2023 audited
FY2024 audited
FY2025 audited
Income statement
Revenue
—
$2,103,579
$2,259,002
$4,018,818
$6,133,120
$9,197,992
$5,858,202
$5,722,379
$3,008,361
$2,065,292
Cost of goods sold
—
—
—
—
—
—
—
—
$7,686,009
—
Gross margin
—
—
—
—
—
—
—
—
-155%
—
Net income
-$1,376,406
-$2,581,011
-$5,790,835
-$5,528,599
-$5,755,256
-$10,412,582
-$8,815,744
-$1,012,203
-$6,131,479
-$3,280,254
Balance sheet
Cash
$58,716
$50,006
$135,778
$110,441
$162,184
$3,291,646
$61,891
$247,222
$76,241
$37,136
Accounts receivable
$146,874
$113,349
$114,884
$83,251
$87,153
$86,287
$72,284
$20,861
$0
—
Total assets
$329,511
$439,783
$427,363
$2,546,554
$8,026,548
$10,694,556
$4,580,716
$4,280,140
$2,222,989
$1,702,346
Short-term debt
—
$70,186
—
—
$722,508
$450,000
$291,650
—
—
—
Long-term debt
—
—
—
—
$17,942
$138,625
$45,000
—
$662,202
—
Total liabilities
$1,241,193
$2,491,196
$3,362,210
$5,389,234
$6,676,540
$3,490,662
$4,266,266
$3,475,410
$5,352,198
$7,464,197
Other
Headcount
—
—
—
—
—
—
—
—
25
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$20.9M
est. pre-money
Reg A+ · Equity · Apr 2025

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jun 30, 2026
preferred stock · 48.2%Common stock · 51.8%
ClassOutstandingVotes / shareShare of totalVotesLast price
preferred stockpreferred2,750,00010048.2%98.9%—
Common stock2,953,225—51.8%1.06%—
Total5,703,225100%100%

Shares outstanding over timein today's share terms

285M142M0
Dec 2016Jun 2026
Common stockpreferred stockRound openedSplit / conversion

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Mar 31, 2026

  • Dr. Michael Dent2,750,000 Series B Preferred Stock100.0%of Series B Preferred
  • Dr. Michael Dent2,604,314 Common Stock55.5%of
  • George O'Leary39,061 Common Stock1.3%of

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Apr 2025Abandonedvia DealMaker
Raised $0 / $10MEst. pre-money $20.9M
Raised $2MInvestors 3
Raised $3.6MInvestors 1
Raised $374KInvestors 12
Raised $96KInvestors 22

Team

8 people
Michael Dent, MD
Chairman of Board of Directors, Chief Executive Officer
Jeremy Daniel
Chief Financial Officer
William Crupi
Chief Operating Officer
Daniel Hall
Director
Dr. Paul Hobaica
Director
George O' Leary
Director
Heather Monahan
Director
Robert Gasparini
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 10-QAug 14, 20260001213900-26-090221
    EDGAR
  • Form 10-QMay 15, 20260001213900-26-057581
    EDGAR
  • Form 10-KMar 31, 20260001213900-26-037499
    EDGAR
  • Form 10-QNov 19, 20250001213900-25-112578
    EDGAR
  • Form 10-QAug 14, 20250001213900-25-076656
    EDGAR
  • Form 10-QMay 15, 20250001213900-25-044233
    EDGAR
  • Form 1-AApr 30, 20250001213900-25-037664
    EDGAR
  • Form 10-KMar 31, 20250001213900-25-026262
    EDGAR
Source: SEC EDGARCIK 0001680139NVShare price $3.25Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.